Abstract
Adolescents and young adults (AYAs; ages 15-39 years) with acute lymphoblastic leukemia (ALL) have worse outcomes than pediatric patients with ALL. Multiple factors contribute to this differential survival. AYAs are more likely to have higher-risk leukemia biology than children with ALL. AYA patients have more choices for treatment facility and treatment protocol, as well as barriers to clinical trial enrollment, both of which can affect survival. AYAs must also navigate psychosocial factors inherent to their unique developmental stage. Furthermore, AYAs typically sustain more treatment-related toxicities than pediatric patients. Treatment on pediatric or pediatric-inspired ALL protocols at pediatric cancer centers has been associated with improved outcomes for AYAs with ALL, but there is still variation in the treatment that AYAs with ALL receive. Clinical trials focused on AYAs with ALL and individualized decision-making regarding choice of treatment facility and treatment protocol are needed to optimize the survival and long-term outcomes of this patient population.
References
1.
Curran
E
, Stock
W.
How I treat acute lymphoblastic leukemia in older adolescents and young adults
. Blood
. 2015
;125
(24
):3702
-3710
. doi:10.1182/blood-2014-11-551481.
2.
Stock
W
, Luger
SM
, Advani
AS
, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
. Blood
. 2019
;133
(14
):1548
-1559
. doi:10.1182/blood-2018-10-881961.
3.
Carroll
AJ
, Shago
M
, Mikhail
FM
, et al. Masked hypodiploidy: hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: a report from the Children's Oncology Group
. Cancer Genet
. 2019
;238
(14
):62
-68
. doi:10.13039/100000002.
4.
Miller
KD
, Fidler-Benaoudia
M
, Keegan
TH
, Hipp
HS
, Jemal
A
, Siegel
RL
. Cancer statistics for adolescents and young adults, 2020
. CA Cancer J Clin
. 2020
;70
(6
):443
-459
. doi:10.3322/caac.21637.
5.
Close
AG
, Dreyzin
A
, Miller
KD
, Seynnaeve
BKN
, Rapkin
LB
. Adolescent and young adult oncology—past, present, and future
. CA Cancer J Clin
. 2019
;69
(6
):485
-496
. doi:10.3322/caac.21585.
6.
Howlader
NNA
, Krapcho
M
, Miller
D
, et al, eds. SEER Cancer Statistics Review, 1975-2017
. National Cancer Institute. https://seer.cancer.gov/csr/1975_2017/. Accessed April
4
, 2023
.7.
Bleyer
A
, Barr
R
, Hayes-Lattin
B
, Thomas
D
, Ellis
C
, Anderson
B.
The distinctive biology of cancer in adolescents and young adults
. Nat Rev Cancer
. 2008
;8
(4
):288
-298
. doi:10.1038/nrc2349.
8.
Rytting
ME
, Jabbour
EJ
, O'Brien
SM
, Kantarjian
HM
. Acute lymphoblastic leukemia in adolescents and young adults
. Cancer
. 2017
;123
(13
):2398
-2403
. doi:10.5772/intechopen.94886.
9.
Stock
W
, La
M
, Sanford
B
, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
. Blood
. 2008
;112
(5
):1646
-1654
. doi:10.1182/blood-2008-01-130237.
10.
Muffly
L
, Alvarez
E
, Lichtensztajn
D
, Abrahão
R
, Gomez
SL
, Keegan
T.
Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study
. Blood Adv
. 2018
;2
(8
):895
-903
. doi:10.1182/bloodadvances.2017014944.
11.
Wolfson
J
, Sun
C-L
, Wyatt
L
, Stock
W
, Bhatia
S.
Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia: impact of care at specialized cancer centers on survival outcome
. Cancer Epidemiol Biomarkers Prev
. 2017
;26
(3
):312
-320
. doi:10.13039/100000002.
12.
Huguet
F
, Leguay
T
, Thomas
X
, et al. The upper age limit for a pediatric-inspired therapy in younger adults with Ph-negative acute lymphoblastic leukemia (ALL)? Analysis of the Graall-2005 Study
. Blood
. 2016
;128
(22
): 762
. doi:10.1182/blood.v128.22.762.
13.
Rytting
ME
, Jabbour
EJ
, Jorgensen
JL
, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen
. A J Hematol
. 2016
;91
(8
):819
-823
. doi:10.1002/ajh.24419.
14.
Gupta
S
, Pole
JD
, Baxter
NN
, et al. The effect of adopting pediatric protocols in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: an IMPACT Cohort study
. Cancer Med
. 2019
;8
(5
):2095
-2103
. doi:10.1002/cam4.2096.
15.
Hughes
N
, Stark
D.
The management of adolescents and young adults with cancer
. Cancer Treat Rev
. 2018
;67
(suppl
):45
-53
. doi:10.1016/j.ctrv.2018.05.001.
16.
Tricoli
JV
, Blair
DG
, Anders
CK
, et al. Biologic and clinical characteristics of adolescent and young adult cancers: acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma
. Cancer
. 2016
;122
(7
):1017
-1028
. doi:10.1002/cncr.29871.
17.
DeAngelo
DJ
, Stevenson
KE
, Dahlberg
SE
, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia
. Leukemia
. 2015
;29
(3
):526
-534
. doi:10.1038/leu.2014.229.
18.
Testi
AM
, Canichella
M
, Vitale
A
, et al. Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial
. Am J Hematol
. 2021
;96
(3
):292
-301
. doi:10.1002/ajh.26066.
19.
Greenwood
M
, Trahair
T
, Sutton
R
, et al. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL
. Blood Adv
. 2021
;5
(24
):5574
-5583
. doi:10.1182/bloodadvances.2021005576.
20.
Boissel
N
, Auclerc
M-F
, Lhéritier
V
, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials
. J Clin Oncol
. 2003
;21
(5
):774
-780
. doi:10.1200/JCO.2003.02.053.
21.
Boissel
NS
, Sender
LS
. Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: a focus on asparaginase
. J Adolesc Young Adult Oncol
. 2015
;4
(3
):118
-128
. doi:10.1089/jayao.2015.0014.
22.
Muffly
L
, Lichtensztajn
D
, Shiraz
P
, et al. Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: a population-based study: analysis of regimens used for ALL in AYAs
. Cancer
. 2017
;123
(1
):122
-130
. doi:10.13039/100014549.
23.
Alacacioglu
I
, Medeni
SS
, Ozsan
GH
, et al. Is the BFM regimen feasible for the treatment of adult acute lymphoblastic leukemia? A retrospective analysis of the outcomes of BFM and hyper-CVAD chemotherapy in two centers
. Chemotherapy
. 2014
;60
(4
):219
-223
. doi:10.1159/000375258.
24.
Schmiegelow
K
, Rank
CU
, Stock
W
, Dworkin
E
, van der Sluis
I.
SOHO state of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia
. Clin Lymphoma Myeloma Leuk
. 2021
;21
(11
):725
-733
. doi:10.13039/100008363.
25.
West
ZE
, Castellino
SM
, Monroe
C
, Thomas
AS
, McCracken
C
, Miller
TP
. Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia
. Leuk Lymphoma
. 2021
;62
(4
):899
-908
. doi:10.1080/10428194.2020.1852471.
26.
Advani
AS
, Larsen
E
, Laumann
K
, et al. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia
. Blood Adv
. 2021
;5
(2
):504
-512
. doi:10.1182/bloodadvances.2020002439.
27.
Bhatia
S
, Landier
W
, Shangguan
M
, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the Children's Oncology Group
. J Clin Oncol
. 2012
;30
(17
):2094
-2101
. doi:10.1200/jco.2011.38.9924.
28.
Senkus
E
, Gomez
H
, Dirix
L
, et al. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98: fertility attitudes in young patients with breast cancer
. Psycho-Oncol
. 2014
;23
(2
):173
-182
. doi:10.1002/pon.3384.
29.
Rosenberg
AR
, Macpherson
CF
, Kroon
L
, Johnson
R.
Rethinking adherence: a proposal for a new approach to risk assessment
. J Adolesc Young Adult Oncol
. 2013
;2
(2
):83
-86
. doi:10.1089/jayao.2012.0025.
30.
Perez
GK
, Salsman
JM
, Fladeboe
K
, Kirchhoff
AC
, Park
ER
, Rosenberg
AR
. Taboo topics in adolescent and young adult oncology: strategies for managing challenging but important conversations central to adolescent and young adult cancer survivorship
. Am Soc Clin Oncol Educ Book
. 2020
;29
(40
):e171
-e185
. doi:10.1200/edbk_279787.
31.
Jacob
SA
, Shaw
PH
. No improvement in clinical trial enrollment for adolescents and young adults with cancer at a children's hospital
. Pediatr Blood Cancer
. 2017
;64
(12
):e26638
. doi:10.1002/pbc.26638.
32.
Ferrari
A
, Montello
M
, Budd
T
, Bleyer
A.
The challenges of clinical trials for adolescents and young adults with cancer
. Pediatr Blood Cancer
. 2008
;50
(suppl 5
):1101
-1104
. doi:10.1002/pbc.21459.
33.
Bleyer
W
, Tejeda
H
, Murphy
S
, et al. National cancer clinical trials: children have equal access; adolescents do not
. J Adolesc Health
. 1997
;21
(6
): 366
-373
. doi:10.1016/s1054-139x(97)00110-9.
34.
Kantarjian
H
, Stein
A
, Gökbuget
N
, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
. N Engl J Med
. 2017
;376
(9
):836
-847
. doi:10.1056/nejmoa1609783.
35.
Winters
A
, Gore
L.
Moving immunotherapy into the front line in ALL
. Hematology
. 2019
;2019
(1
):209
-217
. doi:10.1182/hematology.2019000017.
36.
Hendricks-Ferguson
VL
, Cherven
BO
, Burns
DS
, et al. Recruitment strategies and rates of a multi-site behavioral intervention for adolescents and young adults with cancer
. J Pediatr Health Care
. 2013
;27
(6
):434
-442
. doi:10.1016/j.pedhc.2012.04.010.
37.
Children’s Oncology Group. A phase 3 randomized trial of inotuzumab ozogamicin (IND#:133494, NSC#: 772518) for newly diagnosed high-risk B-ALL; risk-adapted post-induction therapy for high-risk B-ALL, mixed phenotype acute leukemia, and disseminated B-LLy
. 2021
https://childrensoncologygroup.org/aall1732. Accessed April
4
, 2023
.38.
National Comprehensive Cancer Network
. Acute lymphoblastic leukemia
. In: NCCN Clinical Practice Guidelines in Oncology
. 2022
https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1410. Accessed April
4
, 2023
.39.
Siegel
SE
, Advani
A
, Seibel
N
, et al. Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: hyper-CVAD vs. pediatric-inspired regimens
. Am J Hematol
. 2018
;93
(10
):1254
-1266
. doi:10.1002/ajh.25229.
40.
Children’s Oncology Group
. High risk B-precursor acute lymphoblastic leukemia (ALL)
. March
25
, 2013
. Accessed April 4, 2023.Copyright © 2023 by The American Society of Hematology
2023
You do not currently have access to this content.
